Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OSE 2101 |
Synonyms | |
Therapy Description |
OSE 2101 is a cancer vaccine comprising HLA-A2+ restricted modified epitopes targeting CEA, ERBB2 (HER2), TP53, MAGE2, and MAGE3, which may result in activity of an immune response, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2021;9). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OSE 2101 | EP-2101|Tedopi|OSE-2101|OSE2101|IDM2101 | OSE 2101 is a cancer vaccine comprising HLA-A2+ restricted modified epitopes targeting CEA, ERBB2 (HER2), TP53, MAGE2, and MAGE3, which may result in activity of an immune response, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2021;9). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02654587 | Phase III | OSE 2101 Pemetrexed Disodium Docetaxel | Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT06472245 | Phase III | OSE 2101 Docetaxel | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) | Not yet recruiting | USA | 0 |
NCT03806309 | Phase II | OSE 2101 Nivolumab + OSE 2101 Fluorouracil + Irinotecan + Leucovorin | Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM) | Recruiting | FRA | 0 |
NCT04713514 | Phase II | OSE 2101 + Pembrolizumab OSE 2101 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA) | Active, not recruiting | FRA | DEU | BEL | 0 |